Vivos Therapeutics

Rising Sleep Apnea Cases Will Fuel Non-Invasive Therapy Adoption

AnalystHighTarget

Not Invested

Consensus Narrative from 2 Analysts

Published

17 Aug 25

Updated

17 Aug 25

AnalystHighTarget's Fair Value

US$6.20

31.1% undervalued

17 Aug

US$4.27

40.0%

-10.1%

Author's Valuation

US$6.2

31.1% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$6.2

31.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

16.77%

Healthcare Services revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$1.98m

Earnings '28

40.59x

PE Ratio '28

US$80.33m

Market Cap '28

US$80.33m

Market Cap '28

10.64m

No. shares '28

US$7.55

Share Price '28

US$7.55 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$6.20

Fair Value '25